AVBP
NASDAQArriVent BioPharma Inc.
News25/Ratings11
News · 26 weeks34-29%
2025-12-282026-06-21
Mix1490d
- SEC Filings7(50%)
- Insider4(29%)
- Other3(21%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Parsey Merdad4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
- INSIDERSEC Form 4 filed by Director Peterson Kristine4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
- INSIDERSEC Form 4 filed by Director Hohneker John4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
- INSIDERSEC Form 4 filed by Director Nolet Chris4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
- SECArriVent BioPharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - ArriVent BioPharma, Inc. (0001868279) (Filer)
- SECArriVent BioPharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ArriVent BioPharma, Inc. (0001868279) (Filer)
- SECSEC Form 424B5 filed by ArriVent BioPharma Inc.424B5 - ArriVent BioPharma, Inc. (0001868279) (Filer)
- SECSEC Form 10-Q filed by ArriVent BioPharma Inc.10-Q - ArriVent BioPharma, Inc. (0001868279) (Filer)
- SECArriVent BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ArriVent BioPharma, Inc. (0001868279) (Filer)
- PRArriVent BioPharma Reports First Quarter 2026 Financial ResultsTopline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent ADC, advances into the clinic and plans to dose its first patient in 2H 2026, initially for ovarian and endometrial cancers ARR-002's superior anti-tumor activity and favorable tolerability vs. single-target or bivalent approaches in preclinical ovarian cancer models presented at AACRCash and investments of $326.4 million as of March 31, 2026 expected to fund operations into 4Q 2027 NEWTOWN SQUARE, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP
- PRArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial CancersSuperior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approachesPhase 1 initiation expected in the second half of 2026 NEWTOWN SQUARE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ARR-002, a potential first-in-class MUC16/NaPi2b targeting tetravalent antibody-drug conjugate (ADC) with an initial focus in
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ArriVent BioPharma Inc.SCHEDULE 13G/A - ArriVent BioPharma, Inc. (0001868279) (Subject)
- SECSEC Form DEFA14A filed by ArriVent BioPharma Inc.DEFA14A - ArriVent BioPharma, Inc. (0001868279) (Filer)
- SECSEC Form DEF 14A filed by ArriVent BioPharma Inc.DEF 14A - ArriVent BioPharma, Inc. (0001868279) (Filer)
- PRArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual MeetingUnique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal modelsSuperior anti-tumor activity of ARR-002 in ovarian cancer models compared to single-target or bivalent approaches with favorable tolerability underscores best-in-disease ADC potential NEWTOWN SQUARE, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced two poster presentations at the 2026 American Association for Cancer Research (AACR) A
- PRAarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026Aarvik Therapeutics, an innovative, ADC-focused biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce that it will present two posters and a minisymposium talk at the AACR Annual Meeting 2026. These presentations display the breadth of Aarvik's capabilities in the ADC space. The AACR Annual Meeting will take place from April 17-22, 2026, in San Diego, California. Aarvik, along with collaborator ArriVent BioPharma, Inc. (NASDAQ:AVBP), will present a poster titled "AV-P138-ADC (ARR-002), a novel MUC16/NaPi2b dual-target tetravalent ADC, for the treatment of ovarian and endometrial cancers" (Poster Number 2660). AV-P138-ADC, also known
- SECArriVent BioPharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - ArriVent BioPharma, Inc. (0001868279) (Filer)
- ANALYSTBTIG Research resumed coverage on ArriVent BioPharma with a new price targetBTIG Research resumed coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $42.00
- SECSEC Form S-8 filed by ArriVent BioPharma Inc.S-8 - ArriVent BioPharma, Inc. (0001868279) (Filer)
- SECSEC Form 10-K filed by ArriVent BioPharma Inc.10-K - ArriVent BioPharma, Inc. (0001868279) (Filer)
- SECArriVent BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ArriVent BioPharma, Inc. (0001868279) (Filer)
- PRArriVent BioPharma Reports Full Year 2025 Financial ResultsTopline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 first-line PACC mutant NSCLC study for firmonertinib enrollment underwayADC pipeline advancing with first ADC program, ARR-217, in Phase 1 clinical development Cash and investments of $312.8 million as of December 31, 2025 expected to fund operations into 3Q 2027 NEWTOWN SQUARE, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the year ended
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ArriVent BioPharma Inc.SCHEDULE 13G/A - ArriVent BioPharma, Inc. (0001868279) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ArriVent BioPharma Inc.SCHEDULE 13G/A - ArriVent BioPharma, Inc. (0001868279) (Subject)
- PREGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsightThe EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua
AVBP FAQ
6 questionsWhere does AVBP stock trade?
ArriVent BioPharma Inc. (AVBP) is listed on NASDAQ.What sector and industry is AVBP in?
ArriVent BioPharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did ArriVent BioPharma Inc. go public?
ArriVent BioPharma Inc. (AVBP) completed its IPO in 2024.What are analysts saying about AVBP?
ArriVent BioPharma Inc. has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Buy with a $4200.00 price target on 2026-03-12. Recent price targets range from $2500.00 to $4500.00.What companies are similar to AVBP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AVBP side-by-side with any of them on Quantisnow.How can I track AVBP on Quantisnow?
Quantisnow aggregates ArriVent BioPharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AVBP to receive live email and push alerts on every new disclosure.